Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gallon of petrol against the price of a cyto share. Jeezum Crow! Never thought I would see that ugly ratio. My screen shows a low today of $1.89. Is that correct or was that some silly pre-market number on 10 shares? Thanks in advance fellow CTSO followers. Sure glad I only have a few left now. Does anyone think the tanking share price is related to German salesforce issues like it was years back when it was in the $15 zone? Appreciate the thoughts of the heavy thinkers installed here.
Not a word from anyone in an effort to turn this nightmare around! I voted no! They should all be fired!
And not a word from anyone in an effort to turn this nightmare around! I voted no! They should be fired!
Anyone here stupid enough to vote ‘yes’ “To approve, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K”? Of course the BOD recommends ‘For’. How else can they continue to line their pockets at shareholder expense? I’ll vote ‘For’ if they convert at $10/share in the next 12 months but it won’t happen because they won’t see a dime in that scenario.
Anyone wanna take a stab as to when we breach $2/share?
Case of the Week
Literature Database
CytoSorb® usage in a dual antiplatelet agent treated patient during CABG and broken guidewire retrieval from right coronary artery ostium
Kumar N., Keshri V. K., Bhuyan R. R. | Fortis Escorts Heart Institute, New Delhi, India | IJMDAT 2022; 5: e379: epub
04/27/2022
New!Peer Reviewed Published DataSafetyTransfusionsAnti throm. removalAnticoagulation HeparinCardiac surgeryCase of the weekCase reportCPBIntra-Op
Download documentDownload documentLink to source
Summary
CoW 17/2022 – A 66-year-old male patient presented to the hospital with complaints of left sided chest pain radiating to left arm for 1 week as well as acute/severe pain over the last 2 days.
Summary
In this case report a 66-year-old male patient on doublet antiplatelet therapy (DAPT) with ticagrelor and ecospirin underwent percutaneous transluminal coronary angioplasty (PTCA) for triple vessel disease (TVD). During withdrawal part of the guidewire became stuck in the right coronary artery. The patient began to deteriorate clinically (left ventricular ejection fraction reduced to 40% with akinetic walls and early pulmonary edema) so he was taken for emergency on-pump coronary artery bypass graft (CABG) surgery, despite being on DAPT. CytoSorb was added to the cardiopulmonary bypass circuit in an effort to remove the ticagrelor and reduce the risk of bleeding. Post-operatively no bleeding was recorded. The patient demonstrated good pump function and sinus rhythm and was able to be discharged in a stable condition within 7 days of hospitalization including 3 days of intensive care unit stay. According to the authors use of intraoperative CytoSorb – in line with earlier reports – prevented expected substantial postoperative bleeding, which led to short ICU stay and total hospitalization time. The authors conclude that intra-operative use of CytoSorb during emergency cardiac surgery in patients treated with ticagrelor is an effective option which reduces risk of bleeding complications, thereby improving outcomes, reducing costs and minimizing morbidity and mortality.
Case presentation
The patient had a history of type 2 diabetes mellitus and acute coronary syndrome (ACS) with a recent inferior wall myocardial infarction
He was under dual antiplatelet therapy (DAPT) with ticagrelor (90 mg twice daily) and aspirin (150 mg once daily). Additional current medication included the statin rosuvastatin (20 mg once daily), the angiotensin II receptor blocker telmisartan (40 mg once daily), the diuretics furosemide/spironolacton (50 mg once daily), and anti-diabetic metformin (500 mg once daily)
Coronary angiography revealed multiple coronary artery lesions
Overall, the patient had coronary artery disease, inferior wall myocardial infarction and critical triple vessel disease
For treatment of his acute myocardial infarction, primary percutaneous transluminal coronary angioplasty (PTCA) of the right coronary artery (RCA) was performed immediately and thrombolysis in the myocardial infarction (TIMI) III flow was achieved
However, during wire withdrawal, the guidewire got entangled in one of the stent struts and the floppy part was separated from the wire shaft in the RCA ostium
The next day, 2D echocardiography revealed moderate left ventricular dysfunction (left ventricular ejection fraction [LVEF] of 40%) with an akinetic posterior wall, basal inferior wall, and mid basal lateral wall as well as an elevated heart rate of 105/min, and mild mitral regurgitation
A CT scan one day later revealed ground glass opacities with both central and peripheral distribution pointing towards early pulmonary edema
Following several attempts of percutaneous retrieval procedures and given the reduction in LVEF to 40%, the decision was made for surgical removal of the guidewire
The next day, the patient underwent on-pump coronary artery bypass graft surgery (CABG) along with antibiotics and intravenous fluids. Midline sternotomy showed mild cardiomegaly, a dilated aorta, and the PTCA guidewire stuck in the RCA ostium. The patient was heparinized and cardiopulmonary bypass was placed using right axillary artery (RAA) cannulation. During the procedure, the floppy part of the PTCA wire was pulled out gently with forceps. One left internal mammary artery (LIMA) and three reversed saphenous vein grafts (RSVG) were used. Two pacing wires (right atrium and right ventricular) and two chest drains (anterior mediastinal and left pleural) were placed
In order to help reduce bleeding complications in this emergency cardiac surgery scenario by accelerating the removal of the platelet aggregation inhibitor ticagrelor, a CytoSorb hemoadsorption device was integrated into the heart lung machine circuit
Treatment
One CytoSorb adsorber was used for a total surgery time of 6 hours
The CytoSorb cartridge was directly integrated into the heart lung machine circuit
Anticoagulation: heparin
Measurements
Intra- and postoperative blood loss
Cardiac function
Lactate
Renal function
Results
Intraoperatively, optimal hemostasis was achieved. No post-operative bleeding was recorded
The patient demonstrated good pump function and sinus rhythm
Serum lactate decreased from 3.1 pre-surgery to 2.1 mg/dl two days later
Also renal function considerably improved within 2 days following the procedure (urine output from 1750 to 3470 ml/day)
Patient Follow-up
Postoperatively, the patient was transferred to the intensive care unit in a stable state for further observation
He was extubated one day following the surgical procedure
Three units of packed cell volume and fresh frozen plasma were administered during his stay
With a total hospitalization time of 7 days (3 days on intensive care ), the patient was discharged in a stable condition
Conclusion
To the authors’ knowledge, this is the first case to be reported from India utilizing CytoSorb for antiplatelet drug removal during a CABG procedure including guidewire retrieval
In this patient, the intraoperative use of CytoSorb prevented expected substantial postoperative bleeding
Therefore, the intra-operative usage of CytoSorb during emergency cardiac surgery in a patient treated with anti-platelet agents (i.e. ticagrelor) represents an effective option which can help to reduce the risk of bleeding complications, thereby improve outcomes, reduce costs and minimizing morbidity and mortality rates.
I'm thinking Hemo must be real close. Not to mention the next Gen XL filter. Just wait when some other company achieves astounding success with endotoxin and the XL filter is held up like a Lombardi trophy. Yeah, I suppose those promises of $80 per share made by the fellas here could have been a little excessive. Let's go with that over the nefarious commentary shall we gang. I lost track of that Canadien filter group, wouldn't surprise me a bit if Tellum took his near 5 million rewards and headed back to the lab...one never really does know unless of course they have close friends that do.
Laker. Any updates on your Canadian filter company? You were so in love with that back in the day. Seems like you brushed that under the rug ? I dumped this turd a long time ago after years of waiting for refresh.
Hey new Director "Jimy", your free shares are already down 50 cents a share. Welcome to the sh@tshow AKA CTSO
While our stock is down 70% in the last year, Chan's total compensation went UP 28%. Is anybody else awake out there? Does this not piss anyone else off? WHERE IS THIS BOARD OF DIRECTORS?????
I'm planning on moving all my CTSO shares out of TD Ameritrade margin account . They told me years ago that they don't lend out my shares in my margin account to others and now they said they do. So they are making interest multiple times on the same shares. My fees for the shares to buy them on margin and then charging more fees to loan them out again for shorting. What's even more insane is that Chan has supported them with video interviews in the past. Any suggestions on a more ethical online Broker platform please?
"Hello ******,
Thank you for contacting TD Ameritrade. My name is Matthew and I would be happy to help!
"Pursuant to the Margin Agreement provided when you originally applied for your margin account, when you hold a debit balance, or in other words borrow funds on margin, in a margin account TD Ameritrade may lend the shares to other clients or broker dealers. If you would like to avoid your shares being lent out, you can pay down your margin balance and hold the positions with 100% equity within the margin account. You can also do the same and also request to have margin removed from the account if you would like to ensure you don't accidentally go back onto margin in the future.
If you have any other questions, you may reply to this message or contact Client Services at 800-669-3900. We are available 24 hours a day, seven days a week. For faster service, please enter your account number when prompted, so that we can direct your call to a representative best suited to service your request.
Thank you and have a wonderful day!"
Client Services
TD Ameritrade
1-800-669-3900 "
"In light of the fact that shareholders would arrive loaded for bear and looking for scalps, we will once again utilize covid as an excuse to hold a virtual annual meeting. Nevermind that sports are now played indoors in front of 20,000 fans, we are putrid cowards afraid to face the music". And the compensation I posted was wrong. It was actually much more. $1.7 million for Chan. You have to be kidding me.
You people sound like novice investors. I believe you people to be the sound group that were claiming $60 and $80 per share when the stock was running up towards $15 a few years back. The FDA trials they were running back then ended up being futile and are no longer active. They were called RE FRESH and then REFRESH 2. Until we achieve FDA approval with the ability to advertise hard data, this will remain as it is. I'm never comfortable seeing a small cap bio play being run before data. I'm glad I followed that rule here. I wish you all good luck and remind you that management is important, however without a product able to show FDA backed efficacy, really you are trading on hype. Such hype was easily detected in the old program run on this very forum along with other forums run by the same group.
Happy weekend to all CTSO longs!
They’re enhancing shareholder; are you blind? Isn’t that one of the primary functions of company officers and the BOD?
When does someone in a high position pay the price and get shown the door for this horrendous performance? Where's Hemopure to tell us how wonderful they are? Oh, over at yahoo posting as "Greg". Nevermind.
At what shareprice will EVERYONE have had enough of these buffoons?
President My Cousin Vinny total compensation $1.177 MILLION. What exactly does this guy do for that? Someone please tell me. Chan $1.3 MILLION. $2.5 MILLION combined for Laurel and Hardy, Abbott and Costello.
Cytokine mass balance levels in donation after circulatory death donors using hemoadsorption: Case series report
Baroni S, Marudi A, Rinaldi S, Ghedini S, Magistri P, Piero Guerrini G, Olivieri T, Dallai C, Talamonti M, Maccieri J, Benedetto FD, Bertellini E. Int J Artif Organs 2022: epub
04/2022
Summary
This observational case series includes 8 patients who were assessed for the donation after circulatory death (DCD) program for donation of either liver or kidneys. All DCD donor subjects were of a similar age (<60), without critical conditions, and had no known liver or kidney dysfunction. CytoSorb was added to the extracorporeal membrane oxygenator (ECMO) prior to transplantation. Several inflammatory cytokine levels (interleukin – IL6, IL8, IL10, TNF-alpha) were measured before and after the CytoSorb cartridge at various time points over nearly 3hrs, during the normothermic regional perfusion (NPR). Results showed a substantial reduction in IL-10 and TNF-alpha levels during the NPR period with hemoadsorption suggesting effective removal by the device with no evidence of a saturation effect. All livers and kidneys were transplanted from the DCD donors. Receiving patients spent less than 3 days in the intensive care unit and the mean number of days of hospitalization wasbelow 14 days. None of these organs presented with signs of primary non-function or histological necrosis. None of the patients underwent renal replacement therapy during their hospital stay. No apparent device-related adverse events occurred during normothermic perfusion. At the 1-year follow- up, there were no significant complications such as graft rejection or liver stenosis ducts. In summary, this study confirms the use of CytoSorb during normothermic reperfusion in DCD donors where all donor organs could be transplanted without complications or primary non function, and, as the authors write, “may serve as a first in human validation towards a strategy to improve organs and to increase organ availability for donation and reduce the waiting list”.
Case of the Week
Use of CytoSorb in a case of Salmonella typhi–induced gastroenteritis with sepsis associated acute kidney injury
Dr. Abdul Samad Ansari & Dr Mayur Shah | Critical Care Unit, Nanavati Max Super Speciality Hospital, Mumbai, India
04/20/2022
New!Reduction in catecholaminesSafetySeptic ShockAnticoagulation CitrateCase of the weekCase reportCritical CareCRRT post filterInflammatory parameters
Download documentDownload document
Summary
CoW 16/2022 – This case reports on a 54-year-old female patient with a known medical history of diabetes mellitus, hypertension andacute gastroenteritis, who was admitted to the hospital with tachycardia (145/min), tachypnea (40/min), a SpO2 of 70% on room air, hypovolemia and drowsiness.
Case presentation
Prior to admission, the patient had approximately 15 episodes of diarrhea and vomiting over the previous 2 days, fever since the day before admission with oliguria, increasing breathlessness and giddiness for the previous 12 hours
Laboratory examination revealed leukocytosis (18,100/µl) as well as elevated inflammatory parameters (C-Reactive Protein -CRP 230 mg/dL, procalcitonin – PCT elevated)
She further exhibited signs of severe lactic acidosis with a plasma lactate concentration of 8.8 mmol/L as well as increased serum creatinine levels (2.68 mg/dL) indicating impaired renal function
Initial Sequential Organ Failure Assessment (SOFA) score was 12 and APACHE II score was 25
The 2D echo showed generalized left venticular (LV) hypokinesia with an ejection fraction (EF) of 25%
Early empiric antibiotic therapy with meropenem, doxycycline and metronidazole were initiated while awaiting findings from microbiological examinations
These finally confirmed the presence of Enterococcus fecalis in her stool culture as well as Salmonella enteritidis in her blood culture
Meanwhile, aggressive fluid resuscitation was commenced (7 liters over the first 24 hours) and due to progressive hemodynamic instability, administration of multiple vasoactive substances (epinephrine, norepinephrine, and vasopressin) which had to be started and increased up to extremely high dosages
The patient progressed to septic shock with severe lactic acidosis and anuric renal failure
Due to a progressive deterioration also of the pulmonary situation, she was intubated and put on mechanical ventilation, and continuous renal replacement therapy (CRRT) was initiated along with CytoSorb within 6 hours of admission
Treatment
Two consecutive CytoSorb treatments were performed for a total treatment duration of 12 hours (each session for 6 hours)
CytoSorb was used in conjunction with standard of care and CRRT (Prismaflex) run in continuous veno-venous hemodiafiltration (CVVHDF) mode
Blood flow rate: 150 ml/min
Effluent dose: 25ml/kg/hour
Anticoagulation: Regional Citrate Anticoagulation (RCA)
CytoSorb adsorber position: post dialyzer
Measurements
Hemodynamics and vasopressor requirements
Inflammatory parameters (CRP, leucocytes)
Lactate levels
SOFA score
Results
During and after CytoSorb treatment, hemodynamics improved with a more than 50% reduction in vasopressor requirements within 18 hours of CytoSorb treatment. Vasopressors could be completely tapered off 24 hours following the last CytoSorb treatment
Lactate levels initially increased during the first 24 hours from 8.8 to 14 mmol/L followed by a progressive decrease reaching normal values by the end of day 4
CRP and PCT progressively declined and reached normal values by day 5
Treatment was also associated with a reduction in SOFA score from 12 to 7 points in 24 hours
Patient Follow-up
CRRT was converted to sustained low-efficiency dialysis (SLED) after 10 days. Her renal function was completely restored after one and a half months
The patient was transferred from the ICU to the normal ward after 1 month and was then discharged home after a hospital stay of 2 months having made a complete recovery
Conclusion
In this patient with salmonella typhi–induced gastroenteritis resulting in septic shock and pre-renal acute kidney injury, the use of combined CRRT and CytoSorb treatment led to an improvement in hemodynamics with a concomitant decrease in vasopressor requirements, resolution of lactic acidosis and an improvement in overall organ function
The early use of CytoSorb and CRRT, along with standard of care, appears to be a promising therapy for the treatment of septic shock while helping to restore organ function and prevent sequential organ failure
CytoSorb was safe and easy to use in conjunction with CRRT.
NEWS -- CytoSorbents to Report First Quarter 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J., April 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2022 operating and financial results after the market close on May 3, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Conference call details:
Date: Tuesday, May 3, 2022
Time: 4:30 p.m. Eastern
Toll free: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13728663
The live audio webcast and presentation can be accessed via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1541445&tp_key=979468cd12
It is recommended that participants dial in approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations portion of the company's website at https://cytosorbents.com/investor-relations/financial-results/.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31, 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR-D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
mailto://tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-to-report-first-quarter-2022-operating-and-financial-results-301527627.html
SOURCE CytoSorbents Corporation
Eskay is back, just as the shorts have started their full court press. Just a coincidence I'm sure.
NEWS -- CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via distributor partners within the region. With a new direct commercialization presence, CytoSorbents expects to focus its resources and expertise to expand the use of CytoSorb® in hospitals throughout this territory, while providing world-class support and education for physicians and healthcare professionals. The UK is the third largest medical device market in Europe and the sixth largest in the world. CytoSorbents will now directly commercialize its products in 15 countries, with sales in more than 70 countries worldwide.
CytoSorbents recently hired Mr. Shaun Whittemore as Country Manager - UK & Ireland, to drive and coordinate market development in the region. Mr. Whittemore brings 20 years of sales, marketing and product specialist experience supporting large, global medical technology companies including LivaNova, Johnson & Johnson, and Smith+Nephew. Prior to joining CytoSorbents, Mr. Whittemore was most recently Commercial Manager, UK & Ireland at LivaNova.
"I am delighted to be part of this exciting opportunity to further develop and grow the market for CytoSorb in the United Kingdom and the Republic of Ireland and expect to leverage my insight and expertise from a career extending over two decades within the healthcare sector. I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region," said Whittemore.
Dr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents stated, "As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with physicians to improve awareness and usage of CytoSorb in its many applications in critical care and cardiac surgery. We also expect to continue working with the UK's National Health Service (NHS), one of the world's largest and well-renowned healthcare systems, to educate them on the clinical benefits and cost-effectiveness of our technology. To begin with, we plan to highlight last year's NICE Medtech innovation briefing on the use of CytoSorb to reduce the risk of bleeding during cardiothoracic surgery in patients on blood thinning medications in the UK health system. Our direct sales expansion into one of the largest medical device markets in the world is just one of many new initiatives intended to drive our core growth overall."
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31, 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR-D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations and Corporate Communications
(732) 482-9984
mailto://tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-to-expand-direct-sales-of-cytosorb-to-the-united-kingdom-the-sixth-largest-medical-device-market-in-the-world-301525647.html
SOURCE CytoSorbents Corporation
Case of the Week
Literature Database
Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®) – A case report
Erich Moresco, Christopher Rugg, Mathias Ströhle, Matthias Thoma | Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria | Clin Case Rep. 2022;10:e05272.
04/13/2022
New!Peer Reviewed Published DataRhabdomyolysisTraumaImpact on organ supportCase of the weekCase reportCritical CareCRRT (pre or post filter)
Download documentDownload documentLink to source
Summary
CoW 15/2022 – This case reports on a 24-year-old, initially healthy male patient, who suffered a knee dislocation due to a sports trauma.
Summary
In this case report a previously healthy 24 yr old had surgery in a peripheral hospital after dislocating his knee whilst playing sports. During the five hour surgery he had a tourniquet applied to his thigh for 2 hours. The next day he developed brown colored urine and was found to have already impaired kidney function (estimated glomerular filtration rate [eGFR] 50 ml/min/1.73m, serum creatinine [SC] 1.68 mg/dl, creatinine kinase [CK] 89,968 U/l, myoglobin >500 µg/l) so a diagnosis of rhabdomyolysis was made. The patient was transferred to a central hospital for fasciotomy and hematoma evacuation and admitted to the intensive care care (ICU) post operatively. On ICU admission myoglobin was 15,993 µg/l and CK 79,182 U/l. Continuous veno-venous hemofiltration (CVVHF) with an AN69 ST membrane was then started purely so that the patient could be treated with a CytoSorb adsorber. Within 24 hrs of treatment CK levels had reduced by more than 50% (34,630 U/l) and myoglobin by more than 80% (3730 µg/l). Prior to hospital discharge on day 15 he had a fully recovered renal function. In summary, the immediate use of CRRT with the addition of CytoSorb led to the highly efficient reduction in CK and myoglobin concentrations from the blood. The authors speculate that in the future this might justify implementation of CRRT as well as a hemoadsorber such as CytoSorb, as soon as excessive myoglobin peak levels are reached and the cause for this is known. The early use of CRRT with the addition of the adsorber could help to prevent acute kidney injury (AKI) instead of just treating the AKI typically caused by this clinical scenario afterwards.
Case presentation
Surgery was performed with a combined general anesthesia and peripheral nerve block (preoperative blood analysis was as follows: creatine kinase (CK) levels 1300 U/l, estimated glomerular filtration rate (eGFR) 82 ml/min/1.73m², serum creatinine (SC) 1.1 mg/dl
The procedure was performed in a peripheral clinic, lasted 5 hrs, and included the use of a tourniquet around the thigh for approximately 2 hours
The following day after surgery, the patient developed a swollen thigh and brown-colored urine
Laboratory results showed elevated levels of CK (89,968 U/l) and myoglobin (>500 µg/l, unspecified) with an already impaired kidney function (eGFR 50 ml/min/1.73m², SC 1.68 mg/dl)
The patient was promptly transferred to the authors hospital for surgical fasciotomy and hematoma evacuation
Postoperatively, the patient was admitted to the Intensive CareUnit (ICU) for further care
On ICU admission myoglobin and CK levels were 15,993 µg/l and 76,182 U/l, respectively
Continuous renal replacement therapy (CRRT) was promptly initiated, carrying a CytoSorb adsorber column, with no other indications than carrying CytoSorb necessitated the start of CRRT
Treatment
One treatment with CytoSorb was performed for 24 hours
CytoSorb was used in combination with CRRT (Gambro Prismaflex Baxter, Deerfield, USA) run in continuous veno-venous hemofiltration (CVVHF) mode using a AN-69 ST membrane as a hemofilter
Blood ?ow rate: 150 ml/min
Resulting pre-dilution fluid: 1500 ml/hour
Post-dilution fluid: 1000 ml/hour
Withdrawal/ultrafiltration: 100 ml/hour
Anticoagulation: Trisodium citrate
Measurements
Myoglobin and CK plasma levels
eGFR
Results
Within 24 hours, a reduction in CK levels by more than 50% and myoglobin levels by more than 80% was achieved
The eGFR improved from 41 to 61 ml/min/1.73m² throughout the combined CRRT/CytoSorb treatment session
Patient Follow-up
Osmodiuretics (mannitol 15%) were administered intravenously on the first 2 days in ICU (total amount: 500 ml). Additional bicarbonate was not given. Resuscitation fluid therapy was conducted with colloids (Gelofusine® 4%, B. Braun, Melsungen, Germany). Maintenance fluids included balanced crystalloids (ELO-MEL isotone Fresenius Kabi, Bad Homburg, Germany)
CRRT therapy was continued up to the 6th postoperative day and was then stopped
He was eventually transferred to the intermediate care on the 7th day and discharged from hospital on the 16thpostoperative day
The day before hospital discharge laboratory results showed a fully recovered renal function (eGFR 122 ml/min/m², SC 0.78 mg/dl) and normal levels of creatine kinase (161 U/l) and myoglobin (28 µg/l)
Conclusion
In summary, the immediate use of CRRT with the addition of CytoSorb led to the highly efficient reduction in CK and myoglobin concentrations from the blood
The authors speculate that in the future this might justify implementation of CRRT as well as CytoSorb, as soon as excessive myoglobin peak levels are reached and the cause for this is known
The early use of CRRT with the addition of the adsorber could help to prevent acute kidney injury (AKI) instead of just treating the AKI typically caused by this clinical scenario afterwards.
CytoSorb usage in a dual antiplatelet agent treated patient during CABG and broken guidewire retrieval from right coronary artery ostium
Kumar N, Keshri K, Rhuyan RR. IJMDAT 2022; 5: e379
04/06/2022
New!Peer Reviewed Published DataSafetyTransfusionsAnti throm. removalCardiac surgeryCase reportCPBCritical CareIntra-Op
Link to source
Summary
In this case report a 66-year-old male patient on doublet antiplatelet therapy (DAPT) with ticagrelor and ecospirin underwent percutaneous transluminal coronary angioplasty (PTCA) for triple vessel disease (TVD). During withdrawal part of the guidewire became stuck in the right coronary artery. The patient began to deteriorate clinically (left ventricular ejection fraction reduced to 40% with akinetic walls and early pulmonary edema) so he was taken for emergency on-pump coronary artery bypass graft (CABG) surgery, despite being on DAPT. CytoSorb was added to the cardiopulmonary bypass circuit in an effort to remove the ticagrelor and reduce the risk of bleeding. Post-operatively no bleeding was recorded. The patient demonstrated good pump function and sinus rhythm and was able to be discharged in a stable condition within 7 days of hospitalization including 3 days of intensive care unit stay. According to the authors use of intraoperative CytoSorb – in line with earlier reports – prevented expected substantial postoperative bleeding, which led to short ICU stay and total hospitalization time. The authors conclude that intra-operative use of CytoSorb during emergency cardiac surgery in patients treated with ticagrelor is an effective option which reduces risk of bleeding complications, thereby improving outcomes, reducing costs and minimizing morbidity and mortality.
Fantomphan, I agree that Phamtom of the Opera is the greatest of all time. I saw it on Broadway and was amazed. I feel the new hire will assist in growing US sales after FDA approval. Good luck to the both of us.
If your CTSO statement is not severely in the red I congratulate you. Mine is horrifically underwater, even with some "brilliant" averaging down on my part. "It can't go lower than 6! No way". Like you, I'm long the stock. All I pointed out was we were given $740K and promptly gave a newcomer director over $200K in free shares. If this is OK with you, that's fine. It's ridiculous to me. I'll take it back if we find out she streamlined FDA approval. There is so much dead weight at the top here and it's dragging you and me down Bio. Good luck to us. We need it. I forgive you for making fun of my handle, even tho you don't deserve it. It comes from my love of the Broadway show Phantom of the Opera. The greatest of all time.
Fantomwind, I am not sucking wind. I am busy buying the on sale shares.
Sadly but not surprising the market didn't care about this $740K. Where do they get off giving the new director over $200K in free shares while we are all sucking wind?
NEWS -- CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J., April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).
Kathleen Bloch, Chief Financial Officer of CytoSorbents commented, "We are pleased to once again work with the New Jersey Economic Development Authority to monetize our state NOLs and R&D tax credits and generate a source of non-dilutive funding to benefit our cash position. These funds will support our global clinical trial program, as well as manufacturing capacity expansion at our new Princeton, New Jersey facility as we pursue FDA marketing approval of our technology in the United States, among other investments. We have a strong balance sheet and expect to fund our 2022 operating expenses with cash on hand. We plan to continue to participate in this innovative program offered by the NJEDA. We appreciate the support of the NJEDA in facilitating our commitment to developing and commercializing products that are helping to save lives."
The New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss (NOL) and Unused Research and Development Tax Credits (R&D Tax Credits) for at least 80% of the value of the tax benefits to a profitable corporate taxpayer in the State of New Jersey that is not an Affiliated Business. This allows Technology and Biotechnology Businesses with Net Operating Losses to turn their tax losses and credits into cash to buy equipment or facilities, or for other allowable expenditures. The New Jersey Economic Development Authority (NJEDA) determines eligibility, and the New Jersey Division of Taxation determines the value of the tax benefits (NOL and R&D Tax Credits).
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31, 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR-D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
mailto://tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-receives-approximately-740-000-from-the-new-jersey-business-tax-certificate-transfer-program-301519735.html
SOURCE CytoSorbents Corporation
Case of the Week
Literature Database
Use of CytoSorb in septic shock with ARDS in the context of pneumonia and pulmonary hemorrhage with suspected macrophage activation syndrome in systemic lupus erythematosus
Dr. Klaus Kogelmann | Interdisciplinary Intensive Care Medicine, Emden Hospital, Germany
04/06/2022
New!Other indicationsReduction in catecholaminesSafetySeptic ShockImprov. resp functionAnticoagulation CitrateARDSCase of the weekCase reportCritical CareCRRT pre filterInflammatory parameters
Download documentDownload document
Summary
CoW 14/2022 – This case reports on a 35-year-old female patient with systemic lupus erythematosus who presented to hospital with exacerbated encephalopathy under the assumption of an infection after she was found apathetic, disoriented and somnolent, lying at home by the ambulance service.
Case presentation
Her vital signs on admission were as follows: blood pressure 117/79 mmHg, heart rate 103/min, respiratory rate 20/min, body temperature 37.7°C, SaO2 99% on room air
Since her discharge from hospital two weeks previously (initial diagnosis of lupus at that time), she had had recurrent fevers up to 39 degrees, progressive deterioration in her general condition, heavy sweating, as well as diarrhea, nausea, vomiting and associated difficulties with food intake (including her necessary medication such as diclofenac, pantoprazole, metamizole, prednisolone). In addition, she complained of a cough which had been getting worse by the day, and a 2-day history of visual disturbances, lack of concentration, disorientation, and hallucinations
Next to the lupus diagnosis she had a history of tuberculosis in 2000. The patient had up to this point refused any vaccinations against COVID-19 due to an unclear allergy, however, the current COVID-19 PCR test proved negative
The patient was initially admitted to the monitoring station due to symptomatic hyponatremia in the context of persistent vomiting and diarrhea. Under intravenous fluid and NaCl substitution, her clinical condition improved transiently
Due to the dyspnea and cough which had been progressing for several days, the radiological findings and a history of known tuberculosis, miliary tuberculosis was ruled out (PCR negative). Until results were available, the patient was treated empirically with a 4-drug therapy (ethambutol, pyrazinamide, isoniazid, rifampicin)
Then, two days after hospital admission, there was an acute respiratory deterioration requiring emergency intubation
Clinical (bronchoalveolar lavage) and radiological findings revealed pulmonary hemorrhage because of her systemic lupus erythematosus
This was accompanied by a septic/inflammatory picture with markedly elevated procalcitonin (PCT 15.8 pg/ml), C-reactive protein (CRP 60.9 mg/l) and ferritin (4322 ng/ml) levels
Given the pronounced hemodynamic instability, a cardiac output-guided (PiCCO) sepsis therapy consisting of volume, vasopressors and empirical antibiotic therapy (piperacillin/tazobactam) was started
In addition, high-dose hydrocortisone administration (1 g for 5 days) was initiated
At this time, she developed oliguric acute renal failure. Given the pronounced hemodynamic instability with the need for increasing doses of catecholamines (norepinephrine 2.7 mg/h) as well as pronounced hyper-lactatemia (7.7 mmol/L), a CytoSorb hemoadsorber was indicated from the authors’ point of view, which was subsequently initiated together with continuous renal replacement therapy (CRRT)
The diagnosis was septic shock with acute respiratory failure (ARDS) in the context of pneumonia and pulmonary hemorrhage (cumulatively, the patient received a total of 3 units of packed red blood cells)
Treatment
A total of 4 consecutive treatments with CytoSorb were performed over the following 3 days (treatment 1 and 2 for 12 hours each, treatment 3 and 4 for 24 hours each)
CytoSorb was used in combination with CRRT (Multifiltrate, Fresenius Medical Care) run in continuous veno-venous hemodialysis (CVVHD) mode
Blood flow rate: 100-200 ml/min
Anticoagulation: Citrate
CytoSorb adsorber position: pre-hemofilter
Measurements
Hemodynamics and catecholamine doses
Inflammatory parameters
Oxygenation
Results
During the course of the treatment, norepinephrine dosages could be gradually reduced. Already after 7 hours, it could be reduced to 1.6 mg/h and could finally almost completely be discontinued 24 hours after the end of the 4 treatments
CytoSorb treatment was also associated with control of hyperinflammation with a clear reduction in inflammatory parameters (CRP 9.2 mg/l, PCT 2.8 pg/ml 24 hours after the last treatment)
Oxygenation also improved under the combined therapy (P/F ratio before starting CytoSorb 88 mmHg and 24 hours after the last treatment 244 mmHg)
Patient Follow-up
In the context of the clinical picture of an acute abdomen (presumably paralytic ileus) necessitating increasing ventilatory pressures, an abdominal CT was inconclusive, and there was a slight improvement under bowel stimulation
After clear clinical stabilization (hemodynamically stable, minimal catecholamine dosages, and pulmonary improvement), hemodialysis and cytokine adsorption were discontinued and weaning from the respirator commenced
In view of the findings (systemic hyperinflammation, hemorrhage, pancytopenia, ferritin increase, hyponatremia) and after a telephone consultation with colleagues from the rheumatology department of the Red Cross Hospital in Bremen, a macrophage activation syndrome (Hemophagocytic Lymphohistiocytosis – HLH in the context of systemic lupus erythematosus) was decided to be the most conclusive
Transfer of the patient to Münster University Hospital for further diagnosis and antibody therapy of lupus erythematosus
At the time of transfer, the patient was still analgosedated and ventilated, but hemodynamically stable
Conclusions
In this patient with septic shock and ARDS in the context of pneumonia and pulmonary hemorrhage as well as suspected macrophage activation syndrome in the context of systemic lupus erythematosus, combined treatment consisting of standard therapy, CytoSorb hemoadsorption and renal replacement therapy resulted in a significant stabilization in hemodynamics with a reduction in norepinephrine dose, control of the hyperinflammatory situation as well as a significant improvement in respiratory function
Treatment with CytoSorb was safe and feasible without technical problems.
Amen to that! FDA approval on the radar screen soon hopefully.
Thank God! I believe we finally a good business person on board.
CYTOSORBENTS APPOINTS JINY KIM, MBA TO ITS BOARD OF DIRECTORS
MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents’ Board of Directors as a new independent director, effective immediately, for a term expiring at the Company’s 2022 Annual Meeting, scheduled for June 7, 2022, at which time Ms. Kim is expected to stand for re-election.
Al Kraus, Chairman of the Board of CytoSorbents stated, “We are pleased to welcome Jiny as our new independent Board director. She has an extensive background in the medical device industry, with an impressive set of skills, experiences, and perspectives in U.S. and international commercialization, sales, marketing, and business development from leadership roles at market-leading companies like Zimmer Biomet, LivaNova, and Ethicon/Johnson & Johnson. She is expected to further strengthen and diversify the Board at a critical juncture for the Company as we target U.S. expansion and further international growth, and be invaluable in helping to guide the Company to the next level.”
Jiny Kim is currently Vice President, Smart Implants, Technology & Data Solutions at Zimmer Biomet. In this role, she is responsible for leading the end-to-end program and product management for Zimmer Biomet’s “Smart Implant” technology, including product development, data development, and market development. In addition, she is leading the launch of Persona IQ®, a first to market smart knee implant in the U.S.
Prior to Zimmer Biomet, Ms. Kim held the position of Vice President of Global Marketing, Neuromodulation and Depression at LivaNova, where she led key initiatives in clinical and commercial areas to maximize the asset value globally. At Ethicon, Johnson & Johnson Medical Devices, she held multiple roles including in U.S. Sales and Marketing, Business Development (Licensing and Acquisition), and Strategic Global Marketing where she launched and managed significant brands through their full lifecycle. Ms. Kim also held multiple global marketing roles at Edwards Lifesciences in the Critical Care space. She began her medical device career as a post-MBA Operating Room-based Clinical Sales Representative in the Los Angeles territory for Ethicon Biosurgery. Prior to her career in the medical device industry, Ms. Kim held positions as a financial analyst in private equity and in management consulting.
“I am thrilled to join the CytoSorbents Board of Directors and to be part of a values-led company that is helping to save lives with the use of its blood purification technology in critical care and cardiac surgery. It is an honor to join the Board at such a pivotal stage in the Company’s history, and I am looking forward to working with the Board and management to broaden access to CytoSorbents’ unique technology globally, and particularly in the United States, the world’s largest medical device market,” said Ms. Kim.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents commented, “On behalf of the entire Company, we are excited to add Jiny to the Board of Directors and to benefit from her knowledge and keen insight on a wide variety of topics. Of great relevance, Jiny is currently launching the Persona IQ® Smart Knee™ implant in the U.S., which includes an FDA Breakthrough Device Designated component, and will have timely and valuable experience as we look to do the same with DrugSorb™-ATR in the U.S. upon completion of our pivotal U.S. STAR-T and STAR-D trials, and potential future FDA marketing approval.”
Ms. Kim earned her MBA from the MIT Sloan School of Management and is a Fulbright Scholar. She graduated Cum Laude with dual undergraduate degrees from the University of Pennsylvania in Economics (The Wharton School) and Political Science.
https://cytosorbents.com/cytosorbents-appoints-jiny-kim-mba-to-its-board-of-directors/
JGR, what is it that he isn't keeping us updated on?
Don't you love the way our amazing CEO keeps us updated on current events and progress? I have never seen such a self-centered self-serving CEO. He seems happy making his one million two hundred thousand dollars of undeserved salary and benefits. To Hell with the shareholders they don't deserve to know anything. What a Jerk! No wonder our share price is where it is.
Case of the Week
Literature Database
Case Report: Prevention of Rhabdomyolysis-Associated Acute Kidney Injury by Extracorporeal Blood Purification with CytoSorb®
Simon Rauch1,2 *, Andrea Borgato1, Ewald Gruber3, Carlo Leggieri1, Matthias Bock1,4 and Paolo Mario Enrico Seraglio1 | 1 Abteilung für Anästhesie und Intensivmedizin, Krankenhaus "F. Tappeiner", Meran, Italien | 2 Institut für Alpine Notfallmedizin, Eurac Research, Bozen, Italien | 3 Abteilung für Chirurgie, Krankenhaus "F. Tappeiner", Meran, Italien | 4 Abteilung für Anästhesiologie, Perioperative Medizin und Intensivmedizin, Paracelsus Medizinische Privatuniversität, Salzburg, Österreich | Frontiers in Pediatrics 2022; 9:801807
03/30/2022
MyoglobinNew!Peer Reviewed Published DataRhabdomyolysisTraumaAnticoagulation CitrateCase of the weekCase reportCritical CareCRRT (pre or post filter)
Download documentDownload documentLink to source
Summary
CoW 13/2022 – This case reports on a 12-year-old boy, who was hit by a motorcycle while riding his bicycle. The motorcycle ran over the boy’s legs causing an open wound in the right groin with massive bleeding.
Summary
In this case report a 12-year-old boy was hit by a motorcycle whilst riding his bicycle. He received an open wound to his right groin causing massive bleeding leading to hemorrhagic shock. The bleeding was compressed manually and after transfer to hospital, he was taken to the operating room for vascular surgery (repair of the right common vein and artery). A medial and lateral fasciotomy was performed in the lower leg to prevent compartment syndrome. Post-operatively the patient was admitted to intensive care, where over time he started to develop a massive rhabdomyolysis (creatinine kinase [CK] >42,670 U/l and myoglobin >12, 000 µg/l, both upper limits of laboratory detection). Along with fluid resuscitation and despite still normal values of serum creatinine and urea as well as preserved diuresis, the authors decided to initiate continuous veno-venous hemodiafiltration and to add a Cytosorb cartridge to the dialysis circuit to eliminate myoglobin and prevent acute kidney injury (AKI). After 12 hours the CK and myoglobin has substantially decreased, however, over the next 12 hours both parameters started to rise again suggesting saturation of the cartridge. Treatment was then interrupted for 16 hrs, but as both parameters continued to climb, treatment was recommenced with a new adsorber for a further 24 hrs. CK and myoglobin again markedly decreased. The patient was able to be discharged from intensive care after 10 days. The authors conclude that the early use of extracorporeal myoglobin removal with Cytosorb after severe rhabdomyolysis might be a useful option and should be further investigated as a tool to prevent the development of AKI.
Case presentation
Upon arrival of the ambulance and emergency physician the boy was in hemorrhagic shock
The bleeding was compressed manually, intravenous access obtained, 500 mls of crystalloid ?uids and 500 mg of tranexamic acid were administered, and the patient transported to the hospital
A contrast enhanced whole body CT scan was performed in the emergency department which revealed a dissection of the right common femoral artery and laceration of the common femoral vein; peripheral pulses were not palpable
The patient was intubated and taken to the operating theater for vascular surgery; a femoral-femoral bypass with a saphenous graft was made and the common femoral vein, which was found to be completely disrupted, was ligated proximally and distally
A medial and lateral fasciotomy was performed in the lower leg to prevent compartment syndrome
The time from the accident to leg reperfusion was estimated to be 3.5 h
Postoperatively the patient was admitted to the intensive care unit (ICU) and extubated after a few hours
On Doppler ultrasound a normal, triphasic ?ow pro?le was found down to the distal tibial and peroneal artery
Over the next few hours a massive rhabdomyolysis developed with creatinine kinase (CK) and myoglobin values reaching a peak of >42,670 U/l (upper limit of laboratory detection) and >12,000 µg/l (upper limit of laboratory detection), respectively
Balanced crystalloid ?uids were administered intravenously to maintain a urinary output of about 200 mls per hours
Despite still normal values of serum creatinine and urea as well as preserved diuresis, the authors decided to initiate continuous renal replacement therapy (CRRT)
With the rationale to eliminate myoglobin and prevent acute kidney injury (AKI), a CytoSorb hemoadsorption cartridge was additionally integrated into the CRRT circuit
Treatment
Two treatments with CytoSorb were performed separated with a pause interval of 16 hours (both treatments for 24 hours)
CytoSorb was used in combination with CRRT (Prismaflex System, Baxter, Germany) run in Continuous Veno-Venous Hemodiafiltration (CVVHDF) mode
Blood ?ow rate: 150 mls/min
Dialysate ?ow rate: 500 mls/hour
Substitution ?ow rate:1,000 mls/hour
Anticoagulation: regional citrate anticoagulation (RCA)
Measurements
Myoglobin and CK plasma levels
Creatinine and urea plasma levels
Results
Twelve hours after the initiation of CVVHDF plus CytoSorb, CK and myoglobin had substantially decreased, yet, during the subsequent 12 h of extracorporeal treatment an increase in both parameters was noted. Following the 16 hours pause interval and a continued increase in CK and myoglobin levels, a second cycle of CVVHDF plus CytoSorb was started and continued for another 24 resulting in a marked decrease in both CK and myoglobin values with a continued decrease even after discontinuation of extracorporeal therapy
Serum creatinine and urea remained in the normal range also after termination of extracorporeal treatment
Patient Follow-up
The length of stay in the ICU was 10 days, whereafter the patient was transferred to the surgical ward
After another 22 days he was discharged from the hospital
Conclusion
This is the first publication presenting the preventative use of CytoSorb in severe rhabdomyolysis with CytoSorb being started (together with continuous renal replacement therapy) despite normal values of serum creatinine, urea and preserved diuresis, with the target being to prevent AKI via myoglobin removal
The authors conclude that the early use of extracorporeal myoglobin removal with CytoSorb after severe rhabdomyolysis might be a useful option and should be further investigated as a tool to prevent the development of AKI.
I have to agree with you Canes. This used to be a good board at one time, now, not so much. It's a shame. If it ruins ones life so much why bother. There are lots of other stocks out there. I have always bought at the height of the crying so it has helped me. I'm down 25% but i'm still not going anywhere for another 5 years. Could it go to zero? sure. I still believe that it is more likely to go up from here in the next 5 years.
Jackqie, you have no idea who I am. Twit? You POS. This is why I never post on this board...mainly due to people like you. All this board is complaint after complaint. There is absolutely no substance to it.
Oh righteous one. Obviously, you know more than us little ones. What a twit. Of course we can contact the company with our questions. Some of us do. But many of us use the message boards as a means to pose questions and opinions to and with fellow investors. That’s one of the reasons message boards exist. We are all in it together. We don’t need to be lectured by you. Twit
Here is what I don't understand. People ask so many questions on message boards. Why not spend your time sending your questions to the Company instead? That is part of the due diligence I am talking about.
Canes,
I realize that! However, at these bargain basement prices I am simply questioning as to why they are not loading up? I am not referring to their options here. I am questioning why they are not buying more than they currently have with their hard earned dollars. I will continue to remain on hold until I see that they do in tandem and in full force.
Thank you for your response!
A few of them did buy. Go do you due diligence. Any other questions?
Case of the Week
Literature Database
Use of CytoSorb in combined hemorrhagic and septic shock with multiple organ dysfunction following complicated surgery for pancreatic head carcinoma
Dr. Andre Hitzl, PD Dr. Florian Wagner Department of Anesthesia, Intensive Care and Emergency Medicine, Klinikumverbund Allgäu gGmbH, Kempten, Germany
03/23/2022
New!Case of the week
Download documentDownload document
Summary
CoW 12/2022 – This case reports on a 60-year-old male patient who presented to hospital for elective surgical treatment of carcinoma of the pancreatic head.
Case presentation
The patient’s medical history included an axial hiatal hernia as well as the following surgical procedures over the years: goiter surgery, bilateral hip replacements, and bilateral knee replacements
The patient had a Whipples procedure, however severe hemorrhagic shock developed intraoperatively as a result of an accidental portal vein injury requiring massive transfusion and reconstruction of the portal vein. The patient was postoperatively transferred intubated and sedated to the intensive care unit for hemodynamic stabilization
In the context of hemorrhagic shock, the patient required high doses of norepinephrine up to 0.7 µg/kg/min and was temporarily prescribed hydrocortisone as supportive therapy
In addition to ROTEM (rotational thromboelastometry) -guided coagulation therapy and administration of numerous blood products, large amounts of crystalloid and colloid solutions were initially required in order to achieve hemodynamic stabilization given the severe endothelial barrier disturbances and massive volume losses via the abdominal drains. Applying these therapeutic measures, the patient quickly stabilized
Two days after the initial procedure, a second look surgery was performed
His massive fluid losses via the drains but particularly via the inserted vacuum-assisted closure (VAC) pump only slowly decreased over time. During the phase when intra-abdominal anastomosis was not yet established, pancreatic and bile fluids were drained percutaneously via inserted drains. Due to massive distension of the small intestine and impaired venous drainage via the portal vein, surgical drainage was initially not possible
Simultaneously, there was a massive increase in the inflammatory parameters. Therefore, calculated antibiotic therapy with piperacillin/tazobactam was initiated
Also the hemodynamic status deteriorated progressively. Despite intensified fluid therapy, prolonged intravascular hypovolemia developed. Therefore and due to increasing renal retention parameters (creatinine up to 2.6 mg/dl) and oliguria, extracorporeal renal replacement therapy (CRRT) was commenced 4 days after the initial operation
Ischemia and hemorrhagic infarction of the intestine resulted in septic shock with massive barrier disruption (destruction of the glycocalyx) and high volume requirements
Interestingly, despite the high volume turnover, the patient consistently showed good pulmonary gas exchange under ventilation
In addition, as an expression of hyperinflammation serum interleukin IL 6 levels were markedly increased (1600 pg/ml). Therefore, the decision was made early on to additionally start hemoadsorption therapy with CytoSorb
Treatment
A total of two treatments with CytoSorb were performed from the onset of the septic episode (both treatments for 24 hours)
CytoSorb was used in combination with CRRT (MultiFiltrate, Fresenius Medical Care) run in CVVHD mode
Blood flow rate: 100 ml/min
Dialysate flow rate: 2000 ml/h
Anticoagulation: Citrate
Position of CytoSorb adsorber: pre-hemofilter
Measurements
Hemodynamics and requirements for vasoactive substances
Inflammatory parameters
Fluid balance
Results
The hemodynamics situation quickly stabilized and only minor dosages of norepinephrine (up to 0.08 mg/h) were required to maintain stability. After that, there were no further episodes of hemodynamic instability
Already 24 hours after integration of the adsorber, a significant reduction in inflammatory parameters including IL-6 was noticed. Within 24 hours of CytoSorb therapy, IL-6 plasma levels reduced to 41 pg/ml
The positive fluid balance, which reached > 4 litres during the first treatment, clearly declined over the course of the second treatment. 48 hours after the start of CVVHD, a negative fluid balance could be achieved
Patient Follow-Up
After completion of CytoSorb therapy, jejunal segment resection was required due to hemorrhagic infarction. Re-anastomoses by the Whipple approach could finally be performed another 3 days later. A R0 situation (no evidence of tumor cells) was achieved by re-resection in the area of the pancreas followed by direct closure of the abdominal wall
After simultaneous discontinuation of CVVHD and CytoSorb, negative fluid balance was achieved using loop diuretics, qualitative renal function also recovered
Weaning was protracted due to the repeated surgical interventions. 12 days after the initial surgical procedure, the patient was extubated without problems and was breathing spontaneously and adequately
The patient could be transferred to the normal ward in a stable condition. Due to development of a critical illness polyneuropathy, he was referred for neurological rehabilitation
Conclusion
In this patient, the postoperative use of CytoSorb for combined hemorrhagic and septic shock and multiple organ failure following surgery for carcimona of the pancreatic head with a complicated course resulted in hemodynamic stabilization, control of hyperinflammation and improvement in volume status
According to the authors, timely application of CytoSorb therapy in this complex case was presumably, at least in part, responsible for control of the hyperinflammation, preventing progression of further organ system dysfunctions
There was no clotting of the system throughout the treatment period and treatment with CytoSorb was safe and easy. No adverse events were recorded.
Where is our leader and his staff? Why are they not buying?
Anyone! What is going on here?
Case of the Week
Literature Database
Corona, Acute Ischemic Stroke, Malignant Cerebral Edema, and Hemo-adsorption: A Case Report
Mehul Shah1, Zakaria Kaidawala2, Arun Shah3, Rushi Desphande4 | 1,2 Department of Critical Care Medicine, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India | 2 Department of Neurosciences, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India | 3 Department of Nephro Critical Care, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India | 4 Department of Nephro Critical Care, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India | Indian J Crit Care Med 26(2): 235 - 238
03/16/2022
New!Peer Reviewed Published DataPost-OpReduction in catecholaminesSeptic ShockViral infectionCase of the weekCase reportCOVID-19CRRT pre filterInflammatory parameters
Download documentDownload documentLink to source
Summary
CoW 11/2022 – This case reports on a 29-year-old man with diabetes mellitus, who presented to the emergency department with complaints of left sided upper limb and lower limb weakness associated with altered sensorium, vomiting, and hypotension.
Summary
This case includes a young patient with malignant cerebral edema due to an acute cerebrovascular accident, with COVID-19. Due to the massively elevated intra-cranial pressure, he was taken up for life-saving decompression craniotomy amidst a cytokine storm and multiorgan failure. Post operatively he was treated with steroids, antibiotics, and CytoSorb therapy in combination with renal replacement therapy (RRT) for 4 days. During this time his markers of hyperinflammation (interleukin – IL-6 and procalcitonin- PCT) reduced by 99.5 and 98.6%, respectively. Vasopressors were stopped on day 4 and he was successfully weaned off ventilator support after 2 weeks. He was de-cannulated and discharged neurologically stable on day 32. According to the authors CytoSorb therapy with dialysis may have played a significant role in reducing the cytokine storm in the presented case. They conclude that timely detection of COVID-19 and anti-inflammatory and hemoadsorption measures may be helpful in modulating cytokine storm, thereby reducing morbidity and mortality.
Case presentation
He was provisionally diagnosed with stroke, encephalopathy, and was suspected to be in septic shock
In the emergency department, he required high oxygen support to maintain saturation and vasopressor support was commenced
Echocardiography was suggestive of Takotsubo or stress cardiomyopathy
He remained hypotensive with profound acidosis requiring escalation of vasopressor therapy
The non-contrast computed tomography (CT) of the brain revealed a massive right hemispheric infarction with raised intracranial pressure (ICP)
He was immediately transferred to the intensive care unit (ICU), where he was resuscitated with fluid therapy, triple inotropes, broad spectrum antibiotics, and shock dose steroids
He developed anuria with persistent metabolic acidosis, resulting in the initiation of continuous renal replacement therapy (CRRT)
Additionally, a CytoSorb adsorber was integrated into the CRRT circuit for control of the hyperinflammatory response
Initially and over the next few hours, his neurological status deteriorated from a Glasgow Coma Scale Score (GCS) of 14/15 to 7/15 and so he was intubated for airway protection. A repeat CT of the brain revealed massively elevated ICP with midline shift due to malignant cerebral edema, requiring decompressive craniotomy
In the meantime, he was diagnosed as COVID-19 positive with minimal respiratory involvement and was treated with only dexamethasone and continued on CytoSorb therapy along with dialysis
His condition deteriorated further with multiple organ failure including inflammatory mediators (Interleukin -IL-6 of 5600 pg/mL, and procalcitonin – PCT 198 ng/dL) pointing towards a cytokine storm, as seen in septic shock, as well as in critically ill COVID-19 patients. Therefore, treatment with CytoSorb along with dialysis was continued
Treatment
CytoSorb was used in combination with CRRT over a period of 4 days
Measurements
Vasopressor requirements
Markers of hyperinflammation
Results
Vasopressors could be discontinued on day 4
During the time of CytoSorb treatment, his markers of hyperinflammation (IL-6 and PCT) reduced by 99.5 and 98.6%, respectively. Additionally, a decrease in D-dimers and Ferritin was documented during the course of treatment
Patient Follow-up
The patient improved considerably and his ejection fraction also normalized to 60%
A regression in the cerebral edema was noticed on repeat brain CT and he started to obey commands, but left-sided hemiplegia persisted
All blood cultures and infectious focus searches via imaging proved negative
Later, he developed purpura fulminans with digital necrosis and blistering of the skin, however the Doppler ultrasound of his lower limbs were normal
Unfortunately, due to worsening gangrene probably due to the hypercoagulable state from the COVID-19 infection along with diabetes, he had to undergo bilateral lower leg amputations
A tracheostomy was performed in view of prolonged ventilation and he could be finally weaned off ventilator support after 2 weeks
At that time, he also recovered from his renal and liver dysfunctions
Neurologically, he improved with good cognitive function
He was successfully de-cannulated and discharged on day 32, while still on oral anticoagulants and anti-epileptic medication
On follow-up, he was able to ambulate with prosthesis, and is awaiting cranioplasty
Conclusion
This young patient with COVID-19, malignant cerebral edema amidst a cytokine storm, and multi organ failure could be successfully treated with standard acute stroke management for his massive stroke and hemoadsorption therapy, in the course of which could he not only be successfully weaned off vasopressor support but also finally recovered from his multisystem failure
According to the authors, CytoSorb therapy with dialysis may have played a significant role in reducing the cytokine storm in this case
They conclude that timely detection of COVID-19 and anti-inflammatory and hemoadsorption measures may be helpful in modulating a cytokine storm.
biotech, I would be happy to speak to you in private. I spent an hour on the phone with Terri yesterday. Let me know if you want to talk.
canes, easy, the upside is when they obtain FDA approval. I am sure that every other company that has trials in process are also delayed by covid. I hate it also, but covid is still effecting everything.
Chan needs to go ! From an 8 dollar reverse split to this he should be ashamed.
Just my opinion.
Followers
|
241
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27413
|
Created
|
10/18/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |